Analyst Price Targets — TEVA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 4, 2026 12:42 pm | David Amsellem | Piper Sandler | $41.00 | $32.64 | StreetInsider | Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About' |
| January 30, 2026 10:35 am | Glen Santangelo | Barclays | $38.00 | $33.07 | TheFly | Teva price target raised to $38 from $35 at Barclays |
| January 29, 2026 3:18 pm | — | Scotiabank | $40.00 | $32.90 | TheFly | Teva price target raised to $40 from $35 at Scotiabank |
| January 7, 2026 12:22 pm | — | Truist Financial | $36.00 | $32.11 | TheFly | Teva price target raised to $36 from $32 at Truist |
| January 6, 2026 12:37 pm | — | Jefferies | $40.00 | $31.00 | TheFly | Teva price target raised, named a top 2026 idea at Jefferies |
| December 22, 2025 11:44 am | — | Piper Sandler | $40.00 | $30.35 | TheFly | Teva price target raised to $40 from $30 at Piper Sandler |
| December 18, 2025 12:21 pm | — | Goldman Sachs | $35.00 | $30.06 | TheFly | Teva price target raised to $35 from $31 at Goldman Sachs |
| December 8, 2025 9:27 pm | — | Barclays | $35.00 | $28.33 | TheFly | Teva initiated with an Overweight at Barclays |
| December 4, 2025 9:18 pm | — | Scotiabank | $35.00 | $28.41 | TheFly | Teva initiated with an Outperform at Scotiabank |
| November 6, 2025 2:25 pm | Matt Dellatorre | Goldman Sachs | $28.00 | $24.40 | TheFly | Teva price target raised to $28 from $25 at Goldman Sachs |
Latest News for TEVA
AE Wealth Management LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 41.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,027 shares of the company's stock after selling 52,672 shares during the period.
FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum.
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with community-informed and experienced-based information and support.
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities
Teva Pharmaceuticals is undergoing a strategic shift from generics to specialty branded medicines, complex generics, biosimilars, and innovation-led pipeline expansion. TEVA's key growth drivers include Austedo, Ajovy, Uzedy, and especially the late-stage immunology asset Duvakitug, which has shown compelling phase 2b efficacy and durability. Phase 2b data for Duvakitug in ulcerative colitis and Crohn's disease…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.